Big Pharma has a model to make a profit and save lives. So, whats the hold-up? - Blog - Business in Global Society - Harvard Business School https://t.co/KL8qlvRIza
AACR 2023 has begun! OncoResponse has a poster presentation on April 19th, which will publicly introduce for the first time preclinical data regarding our dual-targeting antibodies for LILRB1 and LILRB2. The poster will soon be available on our website. #EliteCancerResponders
We are now two weeks away from presenting at #AACR2023! #OncoResponse's poster will publicly introduce for the first time our preclinical data of dual-targeting antibodies for LILRB1 and LILRB2. The poster presentation will take place April 19th. @AACR#EliteCancerResponders
Abyrx, Inc. announced additional FDA clearances for the company's MONTAGE® Settable, Resorbable Bone Putty as both a bone void filler and cranial bone cement, which follow the highly successful clinical introduction of MONTAGE use on bleeding bone. https://t.co/hhYSOpkrRq
Excited to see Qlaris Bio’s co-founder and CMO, Barbara Wirostko, on @endpts Women in Biopharma ’22 list. She is helping guide the co's effort to develop innovative therapies for debilitating ophthalmic diseases. Canaan's @WendeHutton is on co's BOD. https://t.co/0ygV2CBbKF
Big day for PACT Pharma. Data from 1st study using #CRISPR to substitute a gene in patient’s immune cells to treat cancer presented at #SITC2022 and published in @Nature. Groundbreaking research paves way for cutting-edge therapies. https://t.co/8uKt8tBNnQ
Thrilled to see @HyalexOrtho appear on @BusinessInsider list of biotech startups to watch in next year. Excited to see what CEO @carl_vause and team accomplish. @WendeHutton@JuliePapanek@jesse_yeji
Read full piece with BI subscription at: https://t.co/8wkPzH1Ywz
Exciting to see @OncoResponse's clinical supply agreement with @Regeneron to evaluate #OR2805 in combination with Libtayo. We'll be closely watching the clinical evaluation of this combination. Canaan's @WendeHutton is on the OncoResponse board. https://t.co/0pYLHQ6CK8
IDEAYA announces positive interim data from P2 trial of darovasertib and crizotinib synthetic lethal combo. Provides rational for potential registration-enabling study in metastatic uveal melanoma. Canaan’s @TimShannonMD is chair of the IDEAYA board. https://t.co/TItm81Fp0l
Congrats to Julie and the Day One team! A new day for pediatric cancer patients: Day One's share price doubles on initial data for brain tumor drug https://t.co/sNM7OoLxB6
Today, we welcome Alfonso "Chito" Zulueta to the #Glooko Board of Directors. Learn about his success at @LillyPad in the pharmaceutical industry and the experience he brings as we continue to grow as a #DigitalHealth leader: https://t.co/Bh8901n8pH #BetterTogether
Rondo Therapeutics has emerged from stealth mode with a bang. $67M Series A and ambitions to tackle solid tumors with next-gen #immunooncology platform. Round led by Canaan (@nkjellson) and Red Tree VC (Jon Edwards). PR from Rondo here: https://t.co/BkltggRWHi
Today, #Glooko announced the acquisition of DIABNEXT, a France-based company whose #DigitalHealth platform provides #diabetes#RemotePatientMonitoring and enhances physician-patient collaboration. Learn about Glooko XT, formerly DIABNEXT: https://t.co/NTruCWsRCu #BetterTogether
Like @GlookoInc's own platform, the mobile app from acquisition target @DiabNext automatically takes in readings from continuous glucose monitors, insulin pumps and pens and other devices to help diabetes patients track daily health data. https://t.co/Qqm3WaC0lu